Filings
Finds words inside filing documents. Searching Citius Pharmaceuticals, Inc.'s filings · 56 documents indexed.
26 documents · 51 matches
-
CTXR Citius Pharmaceuticals, Inc. 10-Q 2025-05-14
Item 1A. Risk Factors.
going concern and do not include any adjustments that might result from uncertainty about our ability to continue as a going7 matches in this document -
CTXR Citius Pharmaceuticals, Inc. 10-K 2025-12-23
Item 16. Form 10-K Summary.
going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and has a working7 matches in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-11-04
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-10-26
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 10-Q 2026-08-14
Item 6. Exhibits 37
report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;5 matches in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-08-14
going concern; our ability to regain compliance with Nasdaq’s continued listing standards; our ability to successfully commercialize LYMPHIR and establish1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-06-01
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-05-15
going concern; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 10-Q 2026-05-15
Item 6. Exhibits 37
report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;4 matches in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-04-29
going concern; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-04-24
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-04-24
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-03-31
going concern; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; early-stage1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-03-10
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-03-04
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2026-02-13
going concern; our ability to maintain Nasdaq’s continued listing standards; our reliance on third-party logistics providers, distributors, and specialty1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 10-Q 2026-02-13
Item 6. Exhibits 30
report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;4 matches in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2025-12-23
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2025-12-01
going concern ; our ability to successfully commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third1 match in this document -
CTXR Citius Pharmaceuticals, Inc. 8-K 2025-12-01
going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; physician and patient acceptance of LYMPHIR1 match in this document
Page 1 of 2 · 26 documents